15 results
6-K
EX-99.3
CNTG
Centogene NV
1 Feb 22
CENTOGENE Announces USD 62 Million Aggregate Equity and Debt Financings to Support Growth Plan
9:30am
taken in the interest of the Company to now hand over his roles to Kim Stratton. In only a few months during Andrin's tenure as CEO, he has transformed
6-K
EX-99.2
CNTG
Centogene NV
1 Feb 22
CENTOGENE Announces USD 62 Million Aggregate Equity and Debt Financings to Support Growth Plan
9:30am
. Previously, he held a variety of senior leadership positions in his 13-year tenure at Bayer group, most recently as Head of Drug Discovery and a member
6-K
EX-99.1
CNTG
Centogene NV
8 Jun 21
Current report (foreign)
6:31am
, Probiodrug AG, Proteon Therapeutics Inc. and SpePharm Holdings BV. Prior to his current tenure, he was Head of Business Development Europe and Director
424B4
ltvyyfdi 6uk
10 Jul 20
Prospectus supplement with pricing info
12:55pm
F-1
9qznfz
7 Jul 20
Registration statement (foreign)
5:29pm
20-F
do8sg
23 Apr 20
Annual report (foreign)
9:28am
424B4
f845ecjluwbiphf 2stg
8 Nov 19
Prospectus supplement with pricing info
1:00pm
F-1/A
ka0h5n
28 Oct 19
Registration statement (foreign) (amended)
8:20am
F-1
52s8zkmpw62pn mf725
11 Oct 19
Registration statement (foreign)
4:43pm
DRS/A
3vbj3jyeb az9tth
28 Mar 19
Draft registration statement (amended)
12:00am
DRS/A
m0bf0i3q512qk
18 Dec 18
Draft registration statement (amended)
12:00am
DRS
avqai1j p53ca2bfq
31 Oct 18
Draft registration statement
12:00am
- Prev
- 1
- Next